June 23, 2020 09:42 AM EDT
R&D

Sev­en years af­ter li­cens­ing BTK in­hibitor from Bio­gen, be­lea­guered pen­ny­s­tock biotech part­ner con­cedes de­feat

Amber Tong

A BTK in­hibitor Bio­gen punt­ed out of its pipeline years ago has flopped its first clin­i­cal test.

Sune­sis Phar­ma said it would not be tak­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times